ClinicalTrials.gg
CompletedNCT00002394Updated Jun 24, 2005

Safety and Effectiveness of Giving Lamisil to HIV-Positive Subjects With Thrush Who Have Not Responded to Fluconazole Treatment

An interventional study of Terbinafine hydrochloride in Candidiasis, Oral and HIV Infections, sponsored by Novartis. Completed at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2005-06-24.

Sponsored by Novartis · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies in Candidiasis, Oral with a site in United States — 2 open to participants now, 2 under way, none of them phase 3. Candidiasis, Oral · United States.

Enrollment
9th of 13
30 · median 70
No phase
12 of 26
none open now
Registered
1st of 26
by date

Among the 26 studies in Candidiasis, Oral with a site in United States, this one is the 9th largest by enrollment of the 13 interventional ones that give a count, is one of 12 with no phase, and was the 1st registered.

Candidiasis, Oral

48 studies on the registry are indexed under Candidiasis, Oral; 6 are open to participants now.

Browse Candidiasis, Oral studies →

Open to participants now

2 of the 26 studies in Candidiasis, Oral with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 3 Candidiasis, Oral studies recruiting now, 2 set no upper age limit and 1 stops at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Candidiasis, Oral with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to see if it is safe and effective to give Lamisil to HIV-positive patients with thrush (a fungal infection) that has not responded to fluconazole.

Read the detailed description

This is an open-label, dose-escalating study with up to 2 sequential cohorts. The first 15 patients receive Lamisil for 2 weeks. After 2 weeks, patients considered clinically cured (i.e., absence of removable, white plaques) are removed from treatment; patients not considered clinically cured receive an additional 2 weeks of treatment. At the end of 4 weeks, treatment is discontinued, regardless of clinical cure outcome. If less than 80% of patients are clinically cured after the 4 weeks of treatment, a second cohort of 15 patients receive Lamisil on the same treatment regimen as first cohort (i.e., initial 2-week treatment period, with an additional 2 weeks of treatment for those patients who are not considered clinically cured after 2 weeks of treatment).

03

Conditions studied

  • Candidiasis, Oral
  • HIV Infections

Keywords

  • AIDS-Related Opportunistic Infections
  • Dose-Response Relationship, Drug
  • Fluconazole
  • Antifungal Agents
  • Candidiasis, Oral
  • Drug Administration Schedule
  • terbinafine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

You may be eligible for this study if you:

  • Are at least 18 years old.
  • Have thrush that has not responded to at least 10 days of fluconazole treatment.
  • Are -positive.
  • Are expected to live at least 4 weeks.
  • Are able to take oral medication.

Exclusion criteria

Exclusion Criteria

You will not be eligible for this study if you:

  • Have liver or kidney disease.
  • Have received certain medications.
  • Have a history of serious diarrhea or digestive problems.
  • Are pregnant or breast-feeding.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Intervention model
Parallel assignment
Enrollment
30 participants

Interventions

06

Study locations

9 sites
  • Therafirst Med Ctr
    Fort Lauderdale, Florida 33308, United States
  • Associates in Research
    Fort Myers, Florida 33901, United States
  • Clireco Inc
    Tamarac, Florida 33321, United States
  • Infectious Diseases Research Inc
    Tampa, Florida 33614, United States
  • Northwestern Univ / Division of Infectious Disease
    Chicago, Illinois 60611, United States
  • Saint Michaels Med Ctr / Infectious Disease Resch Dpt
    Newark, New Jersey 071029880, United States
  • St Vincents Hosp / Clinical Research Program
    New York, New York 10011, United States
  • Univ of Texas Med Branch
    Galveston, Texas 77555, United States
  • Hampton Roads Med Specialists
    Hampton, Virginia 23666, United States
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 24, 2005, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00002394
Lead sponsor
Novartis
First posted
Aug 31, 2001
Last update
Jun 24, 2005
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 1999. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Terbinafine

Start the discussion